Morgan Stanley Vincerx Pharma, Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Vincerx Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,750 shares of VINC stock, worth $1,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,750

Previous 19,627 91.08%

Holding current value

$1,242

Previous $99,000 98.99%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.57 - $6.6 $10,189 - $117,988	-17,877 Reduced 91.08%	1,750 $1,000
Q1 2024 Aug 16, 2024	BUY	$1.07 - $8.06 $2,003 - $15,088	1,872 Added 10.54%	19,627 $99,000
Q1 2024 May 15, 2024	BUY	$1.07 - $8.06 $2,003 - $15,088	1,872 Added 10.54%	19,627 $99,000
Q4 2023 Aug 16, 2024	BUY	$0.62 - $1.18 $9,923 - $18,885	16,005 Added 914.57%	17,755 $20,000
Q4 2023 Feb 13, 2024	SELL	$0.62 - $1.18 $4,381 - $8,339	-7,067 Reduced 28.47%	17,755 $20,000
Q3 2023 Nov 15, 2023	BUY	$0.66 - $1.38 $447 - $935	678 Added 2.81%	24,822 $25,000
Q1 2023 May 15, 2023	BUY	$0.9 - $1.51 $1,295 - $2,172	1,439 Added 6.34%	24,144 $25,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $1.32 $8,844 - $18,242	-13,820 Reduced 37.84%	22,705 $23,000
Q3 2022 Nov 14, 2022	SELL	$0.0 - $1.72 $0 - $25,357	-14,743 Reduced 28.76%	36,525 $51,000
Q2 2022 Oct 27, 2022	BUY	$0.0 - $0.0 $0 - $0	18,712 Added 57.48%	51,268 $69,000
Q2 2022 Aug 15, 2022	BUY	$0.0 - $0.0 $0 - $0	18,712 Added 57.48%	51,268 $69,000
Q1 2022 Oct 27, 2022	SELL	$0.0 - $0.0 $0 - $0	-18,712 Reduced 36.5%	32,556 $131,000
Q1 2022 May 13, 2022	BUY	$0.0 - $0.0 $0 - $0	1,723 Added 5.59%	32,556 $131,000
Q4 2021 Feb 14, 2022	SELL	$0.0 - $0.0 $0 - $0	-3,918 Reduced 11.27%	30,833 $314,000
Q3 2021 Nov 15, 2021	BUY	$0.0 - $0.0 $0 - $0	34,751 New	34,751 $562,000

Others Institutions Holding VINC

# of Institutions

Shares Held

10.7M

Call Options Held

Put Options Held

View Full List

About Vincerx Pharma, Inc.

Ticker VINC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,189,800
Market Cap $15M
Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...

More about VINC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account